The Vietnam Chloroquine Treatment on COVID-19 (VICO)
SARS-CoV-2 Infection, COVID-19
About this trial
This is an interventional treatment trial for SARS-CoV-2 Infection focused on measuring SARS-CoV-2, COVID-19, chloroquine
Eligibility Criteria
- Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen < 48 hours prior to randomization, and requiring hospital admission in the opinion of the attending physician.
- Provides written informed consent prior to initiation of any study procedures (or legally authorized representative).
- Understands and agrees to comply with planned study procedures.
- Agrees to the collection of OP swabs and venous blood per protocol.
- Male or female adult ≥18 years of age at time of enrollment.
Sites / Locations
- National Hospital for Tropical Diseases
- Can Gio COVID Hospital
- Cho Ray Hospital
- Cu Chi COVID Hospital
- Hospital for Tropical Diseases
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Control arm
Intervention arm
Patients randomized to the control arm will receive a standard of care therapy (a supportive care/treatment according to VN MoH's guideline).
In addition to standard of care therapy, patients randomized to the intervention arm receive chloroquine phosphate as below. For adult ≥ 53kg: 1000mg (4 tablets) at initial dose (T=0), followed by 500mg (2 tablets) at 6 hours later (T=6), and 500mg (2 tablets) once daily for 9 days. For adult from 45 - 52kg: 875mg (3.5 tablets) at T=0, followed by 500mg (2 tablets) at T=6 and 500mg (2 tablets) once daily thereafter. For adult weighted 38 -<45 kg: 750mg (3 tablets) at T=0, followed by 375mg (1.5 tablets) at T = 6 and 375mg (1.5 tablets) once daily thereafter. For adult weighted <38 kg: 625mg (2.5 tablets) at T=0, followed by 375mg (1.5 tablets) at T=6 and 375mg (1.5 tablets) once daily thereafter. The total duration of treatment with chloroquine will be 10 days.